King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Adher Alsayed
Dr. Adher Alsayed is a Consultant in Medical Oncology specialising in breast cancer, with particular expertise in HER-2 positive and triple-negative breast cancer, metaplastic breast carcinoma, and novel immunotherapy combinations — serving international patients seeking the best breast cancer specialist in Riyadh, Saudi Arabia. His research contributions span over two decades at one of the Middle East's largest breast cancer centres.
- Consultant, Breast Cancer Centre with 20+ years of dedicated breast oncology practice
- Published investigator on HER-2 positive metastatic breast cancer and triple-negative breast cancer trials
- Corresponding author on landmark metaplastic breast cancer immunotherapy research
- Active in prospective clinical trials combining tocilizumab with chemotherapy for TNBC
- Contributor to multidisciplinary breast cancer care involving surgery, radiation, and medical oncology
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
Fellowships & Special Training
- Fellowship — Medical Oncology
- Subspecialty Training in Breast Cancer
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Consultant
Areas of Expertise
Major Conditions Treated
- Early-Stage Breast Cancer (Stage I–III)
- HER-2 Positive Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
- Hormone Receptor-Positive Breast Cancer
- Metastatic Breast Cancer
- HER-2 Positive Invasive Lobular Carcinoma
- Metaplastic Breast Carcinoma
- Breast Cancer in Young Women (≤40 years)
- BRCA1/BRCA2-Related Breast Cancer
- Male Breast Cancer
Sub-specialties
- HER-2 Positive Breast Cancer: Expert in dual HER-2 blockade (trastuzumab + pertuzumab + docetaxel) for metastatic breast cancer — a trusted breast cancer specialist in Riyadh for international patients seeking the best HER-2 targeted therapy in Saudi Arabia.
- Triple-Negative Breast Cancer (TNBC): Novel combination approaches including tocilizumab + cisplatin/docetaxel and checkpoint inhibitor combinations.
- Rare Breast Cancer Subtypes: Management of metaplastic breast carcinoma, invasive lobular carcinoma, and rare presentations with immunotherapy-integrated protocols.
Advanced Procedures & Treatments
- Neoadjuvant and Adjuvant Chemotherapy
- HER-2 Targeted Therapy (Trastuzumab, Pertuzumab, T-DM1, Trastuzumab Deruxtecan)
- Immunotherapy / Checkpoint Inhibitors (Pembrolizumab)
- Hormonal Therapy (Tamoxifen, Aromatase Inhibitors, CDK4/6 Inhibitors)
- PARP Inhibitors (for BRCA-mutated breast cancer)
- Tocilizumab-Based Novel Combinations (Clinical Trial)
- Tumour Molecular Profiling and Oncotype DX Testing
- Bone-Modifying Agents (Bisphosphonates, Denosumab)
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh — Consultant, Breast Cancer Centre, Medical Oncology Section, Oncology Centre (Present)
Academic & Research Roles
- Principal Investigator — Tocilizumab + Cisplatin/Docetaxel Phase 1/2 Trial in TNBC
- Contributor — KFSHRC Multidisciplinary Breast Cancer Tumour Board
Key Achievements
- Corresponding author on landmark case reports of complete response to paclitaxel-immunotherapy in metaplastic breast cancer
- Co-author on HER-2 positive metastatic breast cancer study demonstrating 74.7% objective response rate with dual HER-2 blockade
- Co-author on metaplastic breast carcinoma clinical presentation and prognostic factors (Acta Oncologica 2006)
- Contributor to landmark 867-patient Saudi breast cancer experience showing age ≤40 as independent risk factor for relapse
- Active in rare HER-2 positive invasive lobular carcinoma Arab population research
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- Saudi Oncology Society
Research & Publications
Published Papers (Selected)
- Al-Tweigeri T, Akhtar S, ..., Suleman K, AlSayed A, et al. "Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial." Scientific Reports. 2026. DOI: 10.1038/s41598-026-38465-z.
- Suleman K, Mushtaq AH, ..., Alsayed A. "Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among Arabs." Breast Care. 2021;16(1):59-65. DOI: 10.1159/000506824.
- Alsayed A, AlShanqeeti A, Al-Twegieri T, Ajarim DS, Suleman K, et al. "Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population." American Journal of Case Reports. 2021.
- Alshamsan B, Alshibany A, ..., Alsayed A, et al. "Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer." 2022. PMC8721024.
- Al Sayed AD, Elshenawy MA, Tulbah A, et al. "Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination." American Journal of Case Reports. 2019.
- Elkum N, Dermime S, Ajarim D, ..., Alsayed A, et al. "Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience." BMC Cancer. 2007;7:222.
Ongoing Research & Clinical Interests
- Novel IL-6 pathway inhibition in triple-negative breast cancer
- HER-2 targeted therapy in Arab populations
- Rare breast cancer subtypes (metaplastic, invasive lobular HER-2 positive)
- Predictors of recurrence in young breast cancer patients
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Breast Cancer Medical Oncology Consultation | ₹1,500 – ₹4,000 | $18 – $48 |
| Chemotherapy (per cycle) | ₹20,000 – ₹1,50,000 | $240 – $1,800 |
| HER-2 Targeted Therapy (per cycle, Trastuzumab) | ₹60,000 – ₹1,50,000 | $720 – $1,800 |
| Trastuzumab + Pertuzumab Combination (per cycle) | ₹1,50,000 – ₹3,50,000 | $1,800 – $4,200 |
| Immunotherapy (Pembrolizumab per cycle) | ₹1,50,000 – ₹2,50,000 | $1,800 – $3,000 |
| CDK 4/6 Inhibitor (monthly) | ₹1,00,000 – ₹3,00,000 | $1,200 – $3,600 |
| Oncotype DX Recurrence Score | ₹2,00,000 – ₹3,50,000 | $2,400 – $4,200 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Adher Alsayed use in Breast Cancer treatment?
Dr. Adher Alsayed uses dual HER-2 blockade (trastuzumab + pertuzumab), antibody-drug conjugates (T-DM1, trastuzumab deruxtecan), immune checkpoint inhibitors (pembrolizumab), CDK4/6 inhibitors, PARP inhibitors for BRCA-mutated cancers, Oncotype DX molecular profiling, and investigational IL-6 inhibitor combinations. Virtual consultations are available for international patients. Contact Cancer Rounds for a detailed technology overview.
2. What conditions does Dr. Adher Alsayed specialize in treating?
Dr. Adher Alsayed specialises in all subtypes of breast cancer including HER-2 positive, triple-negative, hormone receptor-positive, metastatic, metaplastic, invasive lobular HER-2 positive, BRCA-related, and male breast cancer. International patients seek his expertise as a breast cancer specialist in Riyadh, Saudi Arabia.
3. How do I book an appointment with Dr. Adher Alsayed?
Appointments with Dr. Adher Alsayed can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Adher Alsayed?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Adher Alsayed, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Adher Alsayed offer second opinions for Breast Cancer cases?
Yes. Second opinion consultations for Breast Cancer can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert breast cancer medical oncologist in Riyadh, Saudi Arabia.
